DarioHealth Corp (NASDAQ:DRIO) saw its shares rise 5.7% on Thursday after the company reported that a major U.S. health insurer - identified as one of the five largest in the country - has expanded its agreement to include Dario’s hypertension management solution in addition to an existing behavioral health deployment.
The insurer’s decision adds cardiometabolic care to the contract and, according to Dario, materially increases the addressable population under that customer relationship. The company said this expansion has the potential to approximately triple the revenue opportunity associated with this particular account.
Management expects that revenue tied to the expanded program will begin appearing in 2026, with a more pronounced revenue impact starting in 2027 and continuing thereafter. The timing implies a multiyear ramp as the insurer deploys the new offering to eligible members.
This development represents the third time a health plan customer has broadened its deployment with Dario beyond the condition initially contracted. Under the terms of the enhanced agreement, eligible members will gain access to Dario’s AI-powered hypertension solution across the full blood pressure continuum - from pre-hypertension through Stage 2 hypertension.
Commenting on the expansion, Dario’s Chief Executive Officer, Erez Raphael, said: "This expansion reflects the commercial strategy we’ve been executing for several years. We establish strong partnerships by delivering measurable engagement, clinical outcomes and member satisfaction, then expand those relationships across additional chronic conditions."
DarioHealth currently works with 12 health plan customers, including three national carriers, and offers six chronic condition solutions. The company emphasizes that its integrated platform allows health plans to roll out multiple evidence-based chronic condition programs using a single technology platform and unified member experience.
Company statements frame the expanded agreement as validation of Dario’s multi-condition strategy, which aims to deliver integrated care spanning the entire clinical continuum - from prevention and rising-risk members to those with complex chronic conditions.
Context for markets and payers
From a commercial standpoint, the expansion touches several market axes: payer program design, digital chronic care offerings, and the unit economics of multi-condition deployments. By attaching an additional chronic condition to an existing behavioral health relationship, Dario may increase per-member revenue and improve the lifetime value of the account - outcomes noted by management as drivers of the revenue opportunity uplift under this contract.
Because the revenue contribution is expected to materialize in 2026 and accelerate in 2027, investors and industry stakeholders will likely monitor enrollment, engagement metrics, and payer rollout timing as key indicators of realized financial impact.